Skip to main content
. Author manuscript; available in PMC: 2015 Mar 1.
Published in final edited form as: Cancer Discov. 2014 Sep;4(9):988–990. doi: 10.1158/2159-8290.CD-14-0738

Figure 1.

Figure 1

The impaired function of the MRN complex due to a somatic mutation of Rad50 leads to a synthetic lethality in cancer cells when they are treated with Chk1 inhibitor and DNA-damaging chemotherapy irinotecan.